130 related articles for article (PubMed ID: 38263717)
1. Identification and assessment of new PIM2 inhibitors for treating hematologic cancers: A combined approach of energy-based virtual screening and machine learning evaluation.
Chen X; Zhao J; Chen R; Shen L; Lu J; Guo Y; Chi X; Geng S; Zhang Q; Pan Z; He X; Xu L; Shen Z; Yang H; Lei T
Arch Pharm (Weinheim); 2024 Apr; 357(4):e2300516. PubMed ID: 38263717
[TBL] [Abstract][Full Text] [Related]
2. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
[TBL] [Abstract][Full Text] [Related]
3. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
4. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
[TBL] [Abstract][Full Text] [Related]
5. The PIM kinases in hematological cancers.
Alvarado Y; Giles FJ; Swords RT
Expert Rev Hematol; 2012 Feb; 5(1):81-96. PubMed ID: 22272708
[TBL] [Abstract][Full Text] [Related]
6. Targeting Pim kinases in hematological cancers: molecular and clinical review.
Bellon M; Nicot C
Mol Cancer; 2023 Jan; 22(1):18. PubMed ID: 36694243
[TBL] [Abstract][Full Text] [Related]
7. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.
Saurabh K; Scherzer MT; Shah PP; Mims AS; Lockwood WW; Kraft AS; Beverly LJ
Oncotarget; 2014 Sep; 5(18):8503-14. PubMed ID: 25238262
[TBL] [Abstract][Full Text] [Related]
8. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
9. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel selective PI3Kγ inhibitors through combining machine learning-based virtual screening with multiple protein structures and bio-evaluation.
Zhu J; Li K; Xu L; Cai Y; Chen Y; Zhao X; Li H; Huang G; Jin J
J Adv Res; 2022 Feb; 36():1-13. PubMed ID: 35127160
[TBL] [Abstract][Full Text] [Related]
11. PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma.
Gómez-Abad C; Pisonero H; Blanco-Aparicio C; Roncador G; González-Menchén A; Martinez-Climent JA; Mata E; Rodríguez ME; Muñoz-González G; Sánchez-Beato M; Leal JF; Bischoff JR; Piris MA
Blood; 2011 Nov; 118(20):5517-27. PubMed ID: 21937691
[TBL] [Abstract][Full Text] [Related]
12. Engineered Fully Human Single-Chain Monoclonal Antibodies to PIM2 Kinase.
Kaewchim K; Glab-Ampai K; Mahasongkram K; Chulanetra M; Seesuay W; Chaicumpa W; Sookrung N
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770845
[TBL] [Abstract][Full Text] [Related]
13. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
Hospital MA; Jacquel A; Mazed F; Saland E; Larrue C; Mondesir J; Birsen R; Green AS; Lambert M; Sujobert P; Gautier EF; Salnot V; Le Gall M; Decroocq J; Poulain L; Jacque N; Fontenay M; Kosmider O; Récher C; Auberger P; Mayeux P; Bouscary D; Sarry JE; Tamburini J
Leukemia; 2018 Mar; 32(3):597-605. PubMed ID: 28914261
[TBL] [Abstract][Full Text] [Related]
14. PIM3 Kinase: A Promising Novel Target in Solid Cancers.
Atalay P; Ozpolat B
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339286
[TBL] [Abstract][Full Text] [Related]
15. Targeting PIM kinases in cancer therapy: An update on pharmacological small-molecule inhibitors.
Chen S; Yang Y; Yuan Y; Bo Liu
Eur J Med Chem; 2024 Jan; 264():116016. PubMed ID: 38071792
[TBL] [Abstract][Full Text] [Related]
16. Phytoconstituents and Medicinal Plants for Anticancer Drug Discovery: Computational Identification of Potent Inhibitors of PIM1 Kinase.
Anjum F; Mohammad T; Almalki AA; Akhtar O; Abdullaev B; Hassan MI
OMICS; 2021 Sep; 25(9):580-590. PubMed ID: 34448628
[TBL] [Abstract][Full Text] [Related]
17. PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy.
Musiani D; Hammond DE; Cirillo L; Erriquez J; Olivero M; Clague MJ; Di Renzo MF
J Proteome Res; 2014 Nov; 13(11):4970-82. PubMed ID: 25099161
[TBL] [Abstract][Full Text] [Related]
18. Identification of Potential JNK3 Inhibitors: A Combined Approach Using Molecular Docking and Deep Learning-Based Virtual Screening.
Yao C; Shen Z; Shen L; Kadier K; Zhao J; Guo Y; Xu L; Cao J; Dong X; Yang B
Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895928
[TBL] [Abstract][Full Text] [Related]
19. The role of PIM1/PIM2 kinases in tumors of the male reproductive system.
Jiménez-García MP; Lucena-Cacace A; Robles-Frías MJ; Narlik-Grassow M; Blanco-Aparicio C; Carnero A
Sci Rep; 2016 Nov; 6():38079. PubMed ID: 27901106
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.
Bullock AN; Russo S; Amos A; Pagano N; Bregman H; Debreczeni JE; Lee WH; von Delft F; Meggers E; Knapp S
PLoS One; 2009 Oct; 4(10):e7112. PubMed ID: 19841674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
